{
 "name": "永信",
 "slug": "tw-3705",
 "aliases": [
  "永信國際投資控股股份有限公司",
  "Y.S.H.",
  "3705"
 ],
 "ticker": "3705",
 "industry": "生技醫療業",
 "website": "www.yungshingroup.com",
 "summary": "永信（3705）是上市的生技醫療類股公司，2011 年成立，2011 年上市。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "永信國際投資控股股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "英文簡稱",
   "value": "Y.S.H.",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "掛牌市場",
   "value": "臺灣證券交易所上市",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "上市日期",
   "value": "2011-01-03",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "成立日期",
   "value": "2011-01-03",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "董事長",
   "value": "李芳信",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "總經理",
   "value": "簡志維",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "實收資本額",
   "value": 2664229830,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "安侯建業聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "公司網址",
   "value": "www.yungshingroup.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 659228,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap05_L",
   "note": "原檔數值、單位與as_of保留；2026-10-23核對官方115年9月申報資料（出表1151017），百分比按原檔保留兩位小數。原source為valueledger次級網址混入中文說明，改為可直接開啟的一手API。"
  },
  {
   "claim": "月營收年增率（2026-09）",
   "value": 8.74,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap05_L",
   "note": "原檔數值、單位與as_of保留；2026-10-23核對官方115年9月申報資料（出表1151017），百分比按原檔保留兩位小數。原source為valueledger次級網址混入中文說明，改為可直接開啟的一手API。"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": -6.98,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap05_L",
   "note": "原檔數值、單位與as_of保留；2026-10-23核對官方115年9月申報資料（出表1151017），百分比按原檔保留兩位小數。原source為valueledger次級網址混入中文說明，改為可直接開啟的一手API。"
  },
  {
   "claim": "產品許可：FELODIPINE（TABLET, EXTENDED RELEASE）",
   "value": "FDA ANDA 204800｜美國｜2019-04-29",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://api.fda.gov/drug/drugsfda.json?search=sponsor_name%3A%22YUNG%20SHIN%20PHARM%22&limit=100",
   "note": "申請人YUNG SHIN PHARM。FDA官方資料meta.last_updated=2026-10-21作為as_of；原始核准日取ORIG/AP submission_status_date=20190429。目前API所列產品marketing_status=Prescription。此為歷史學名藥核准記錄，不推定本期營收或銷售地區擴張。"
  },
  {
   "claim": "產品許可：CLONIDINE HYDROCHLORIDE（TABLET）",
   "value": "FDA ANDA 202297｜美國｜2013-06-13",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://api.fda.gov/drug/drugsfda.json?search=sponsor_name%3A%22YUNG%20SHIN%20PHARM%22&limit=100",
   "note": "申請人YUNG SHIN PHARM。FDA官方資料meta.last_updated=2026-10-21作為as_of；原始核准日取ORIG/AP submission_status_date=20130613。目前API所列產品marketing_status=Prescription。此為歷史學名藥核准記錄，不推定本期營收或銷售地區擴張。"
  },
  {
   "claim": "產品許可：CEPHALEXIN（FOR SUSPENSION）",
   "value": "FDA ANDA 065336｜美國｜2007-07-25",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://api.fda.gov/drug/drugsfda.json?search=sponsor_name%3A%22YUNG%20SHIN%20PHARM%22&limit=100",
   "note": "申請人YUNG SHIN PHARM。FDA官方資料meta.last_updated=2026-10-21作為as_of；原始核准日取ORIG/AP submission_status_date=20070725。目前API所列產品marketing_status=Prescription。此為歷史學名藥核准記錄，不推定本期營收或銷售地區擴張。"
  },
  {
   "claim": "產品許可：MELOXICAM（TABLET）",
   "value": "FDA ANDA 077918｜美國｜2006-12-07",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://api.fda.gov/drug/drugsfda.json?search=sponsor_name%3A%22YUNG%20SHIN%20PHARM%22&limit=100",
   "note": "申請人YUNG SHIN PHARM。FDA官方資料meta.last_updated=2026-10-21作為as_of；原始核准日取ORIG/AP submission_status_date=20061207。目前API所列產品marketing_status=Prescription。此為歷史學名藥核准記錄，不推定本期營收或銷售地區擴張。"
  },
  {
   "claim": "產品許可：CEFACLOR（CAPSULE）",
   "value": "FDA ANDA 065146｜美國｜2004-01-22",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://api.fda.gov/drug/drugsfda.json?search=sponsor_name%3A%22YUNG%20SHIN%20PHARM%22&limit=100",
   "note": "申請人YUNG SHIN PHARM。FDA官方資料meta.last_updated=2026-10-21作為as_of；原始核准日取ORIG/AP submission_status_date=20040122。目前API所列產品marketing_status=Prescription。此為歷史學名藥核准記錄，不推定本期營收或銷售地區擴張。"
  },
  {
   "claim": "產品許可：CEFACLOR（FOR SUSPENSION）",
   "value": "FDA ANDA 065412｜美國｜2012-02-17",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://api.fda.gov/drug/drugsfda.json?search=sponsor_name%3A%22YUNG%20SHIN%20PHARM%22&limit=100",
   "note": "申請人YUNG SHIN PHARM。FDA官方資料meta.last_updated=2026-10-21作為as_of；原始核准日取ORIG/AP submission_status_date=20120217。目前API所列產品marketing_status=Prescription。此為歷史學名藥核准記錄，不推定本期營收或銷售地區擴張。"
  },
  {
   "claim": "產品許可：ENTECAVIR（TABLET）",
   "value": "FDA ANDA 208195｜美國｜2021-11-10",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://api.fda.gov/drug/drugsfda.json?search=sponsor_name%3A%22YUNG%20SHIN%20PHARM%22&limit=100",
   "note": "申請人YUNG SHIN PHARM。FDA官方資料meta.last_updated=2026-10-21作為as_of；原始核准日取ORIG/AP submission_status_date=20211110。目前API所列產品marketing_status=Prescription。此為歷史學名藥核准記錄，不推定本期營收或銷售地區擴張。"
  },
  {
   "claim": "產品許可：DICLOFENAC SODIUM AND MISOPROSTOL（TABLET, DELAYED RELEASE）",
   "value": "FDA ANDA 205143｜美國｜2020-02-19",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://api.fda.gov/drug/drugsfda.json?search=sponsor_name%3A%22YUNG%20SHIN%20PHARM%22&limit=100",
   "note": "申請人YUNG SHIN PHARM。FDA官方資料meta.last_updated=2026-10-21作為as_of；原始核准日取ORIG/AP submission_status_date=20200219。目前API所列產品marketing_status=Prescription。此為歷史學名藥核准記錄，不推定本期營收或銷售地區擴張。"
  },
  {
   "claim": "管線：刺激膠原蛋白增生植入劑",
   "value": "醫學美容｜已完成量產製程，待取證｜地區未揭露",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.yungshingroup.com/uploads/images/ir/financial/2026annualreport.pdf",
   "note": "2025年報封面刊印日2026-03-31；PDF第62頁（印刷頁59），產品屬子公司永信藥品。原文未列證號、核准日期或取證時程，不列產品許可或未來催化劑。"
  },
  {
   "claim": "主要產品：玻尿酸關節腔注射劑",
   "value": "子公司永信藥品之醫療器材產品；年報揭露多項已陸續上市",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.yungshingroup.com/uploads/images/ir/financial/2026annualreport.pdf",
   "note": "2025年報PDF第62頁（印刷頁59）；未將上市敘述轉寫為欠缺字號及核准日的許可fact。"
  },
  {
   "claim": "主要產品：醫美皮下注射劑",
   "value": "子公司永信藥品之醫療器材產品；年報揭露已陸續上市",
   "unit": "",
   "as_of": "2026-03-31",
   "source": "https://www.yungshingroup.com/uploads/images/ir/financial/2026annualreport.pdf",
   "note": "2025年報PDF第62頁（印刷頁59）；與尚待取證之刺激膠原蛋白增生植入劑分開記錄。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-23",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-3705.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}